The European Patent Office issued publication EP3417859A1, a patent application for a nanoparticle anticancer agent combining rapamycin with albumin, filed by Abraxis BioScience, LLC. The patent covers compositions classified under IPC A61K 31/436, A61K 9/51, and A61P 35/00, among others, relating to pharmaceutical nanoparticle formulations for cancer treatment. Designated states include all EPC contracting states (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR).\n\nThis is a routine patent publication notice with no compliance obligations. Pharmaceutical companies developing rapamycin-based or albumin nanoparticle formulations should review the patent claims to assess freedom-to-operate for their products. No action is required from compliance teams unless the organization is actively developing competing formulations in the European market. Patent term typically extends 20 years from filing date.